{"name":"Fertility Biotech AG","slug":"fertility-biotech-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AFOLIA","genericName":"AFOLIA","slug":"afolia","indication":"Infertility or subfertility (indication under Phase 3 investigation)","status":"phase_3"},{"name":"Gonal-f® RFF","genericName":"Gonal-f® RFF","slug":"gonal-f-rff","indication":"Infertility in women undergoing assisted reproductive technology (ART) including in vitro fertilization (IVF)","status":"marketed"}]}],"pipeline":[{"name":"AFOLIA","genericName":"AFOLIA","slug":"afolia","phase":"phase_3","mechanism":"AFOLIA is a folate receptor alpha (FRα) antagonist designed to modulate immune responses and enhance fertility outcomes.","indications":["Infertility or subfertility (indication under Phase 3 investigation)"],"catalyst":""},{"name":"Gonal-f® RFF","genericName":"Gonal-f® RFF","slug":"gonal-f-rff","phase":"marketed","mechanism":"Gonal-f RFF is a recombinant human follicle-stimulating hormone (FSH) that stimulates the growth and maturation of ovarian follicles in women undergoing fertility treatment.","indications":["Infertility in women undergoing assisted reproductive technology (ART) including in vitro fertilization (IVF)","Anovulation in women with polycystic ovary syndrome (PCOS) or other causes of anovulation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE00Y25wUTFIUlJSLXh5dGtJSU5FU0d6OVhYaS1zX2YzTGFfenBUWFVCR05GTG9JLUxMVWo4Zy03djJLSnJGOHJ5RTVnTE42cXB2Rk1NT19KdWhRek1ZQ2d6ajIxdnY?oc=5","date":"2025-06-13","type":"pipeline","source":"Market.us","summary":"Infertility Treatment Market Size, Trend analysis | CAGR of 8.2% - Market.us","headline":"Infertility Treatment Market Size, Trend analysis | CAGR of 8.2%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1aRjhrMVpYRVVGYzQxRnk1b2NVLVRxMnEtOWtQRWtVZjdDb2EwVVoyWVhIT3RaamV0TDh5eS1XaHRUUW9heS1fQlBUb1RxaERCajViNlN5aDVuSXFQakRnSDJOaGJjSXhnMnRYd1ZYRTdrbmtDMzZEYw?oc=5","date":"2025-04-09","type":"pipeline","source":"Future Market Insights","summary":"Infertility Drugs Market Size, Trends & Forecast 2025-2035 - Future Market Insights","headline":"Infertility Drugs Market Size, Trends & Forecast 2025-2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxORGxETjVRSlV3MGR0cm5ZYjhlVW5ESGhwakZBWE04ZlEtQjVNRVF6aWxDWWVZWmY1OC1NRnpMQk1UMjRjOTMzS0cxMmxJbXRtbHk2MmE0cGlJYjU0ZmJwOWlIRXV1bzdKTDJZNlJxMktYYjRuQXR3SHp2ZzZidjRzUW9n?oc=5","date":"2024-10-24","type":"deal","source":"pharmaphorum","summary":"Bayer partners medtech firm Impli on fertility R&D - pharmaphorum","headline":"Bayer partners medtech firm Impli on fertility R&D","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}